Announcements Trials

Browse Landscape

Phase

Phase 2 13 Phase 1 6 Phase 1/2 3 Phase 4 1 Phase 3 1

Status

Completed 2 Active not recruiting 2 Withdrawn 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

Carboplatin 98 Cisplatin 95 pembrolizumab 90 Gemcitabine 81 Paclitaxel 80 Docetaxel 73 Capecitabine 64 Oxaliplatin 53 Specimen Handling 52 Fluorouracil 52 Magnetic Resonance Spectroscopy 50 Bevacizumab 49 Radiotherapy 48 Dexamethasone 45 Cyclophosphamide 44 Leucovorin 39 Drug Therapy 39 Irinotecan 37 Doxorubicin 36 Pemetrexed 35 Injections 30 Trastuzumab 28 Vincristine 27 Rituximab 27 Radiosurgery 25 Prednisone 25 Etoposide 25 130-nm albumin-bound paclitaxel 25 Radiation 24 Letrozole 24

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Recruiting × lutetium Lu 177 dotatate × Clear all

NCT06878664 2025-09-02

RIALTO

Grupo Espanol de Tumores Neuroendocrinos

Phase 3 Recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡